Hohensee et al. performed genome-wide mutation profiling on primary BC and BCBM tissue and were able to show that aberrations in the EGFR and HER2 signaling pathways were significantly more common in BCBM tissue than that of primary tumors or other distant metastases. Here, ERBB2 is linked to breast cancer.